244 related articles for article (PubMed ID: 18949619)
1. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.
Navas T; Zhou L; Estes M; Haghnazari E; Nguyen AN; Mo Y; Pahanish P; Mohindru M; Cao T; Higgins LS; Platanias LC; List A; Verma A; Bhagat T; Gajavelli S; Kambhampati S
Leuk Lymphoma; 2008 Oct; 49(10):1963-75. PubMed ID: 18949619
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.
Navas TA; Mohindru M; Estes M; Ma JY; Sokol L; Pahanish P; Parmar S; Haghnazari E; Zhou L; Collins R; Kerr I; Nguyen AN; Xu Y; Platanias LC; List AA; Higgins LS; Verma A
Blood; 2006 Dec; 108(13):4170-7. PubMed ID: 16940419
[TBL] [Abstract][Full Text] [Related]
3. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
[TBL] [Abstract][Full Text] [Related]
4. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.
Katsoulidis E; Li Y; Yoon P; Sassano A; Altman J; Kannan-Thulasiraman P; Balasubramanian L; Parmar S; Varga J; Tallman MS; Verma A; Platanias LC
Cancer Res; 2005 Oct; 65(19):9029-37. PubMed ID: 16204077
[TBL] [Abstract][Full Text] [Related]
5. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.
Zhou L; Opalinska J; Verma A
Cell Cycle; 2007 Mar; 6(5):534-7. PubMed ID: 17351344
[TBL] [Abstract][Full Text] [Related]
6. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome.
Flores-Figueroa E; Gutiérrez-Espíndola G; Montesinos JJ; Arana-Trejo RM; Mayani H
Leuk Res; 2002 Jul; 26(7):677-86. PubMed ID: 12008086
[TBL] [Abstract][Full Text] [Related]
8. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.
Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL
J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease.
Docena G; Rovedatti L; Kruidenier L; Fanning A; Leakey NA; Knowles CH; Lee K; Shanahan F; Nally K; McLean PG; Di Sabatino A; MacDonald TT
Clin Exp Immunol; 2010 Oct; 162(1):108-15. PubMed ID: 20731675
[TBL] [Abstract][Full Text] [Related]
10. Cytokine targets in the treatment of myelodysplastic syndromes.
Verma A; List AF
Curr Hematol Rep; 2005 Nov; 4(6):429-35. PubMed ID: 16232378
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
[TBL] [Abstract][Full Text] [Related]
12. FANCA and FANCC modulate TLR and p38 MAPK-dependent expression of IL-1β in macrophages.
Garbati MR; Hays LE; Keeble W; Yates JE; Rathbun RK; Bagby GC
Blood; 2013 Oct; 122(18):3197-205. PubMed ID: 24046015
[TBL] [Abstract][Full Text] [Related]
13. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
15. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Bachegowda L; Morrone K; Winski SL; Mantzaris I; Bartenstein M; Ramachandra N; Giricz O; Sukrithan V; Nwankwo G; Shahnaz S; Bhagat T; Bhattacharyya S; Assal A; Shastri A; Gordon-Mitchell S; Pellagatti A; Boultwood J; Schinke C; Yu Y; Guha C; Rizzi J; Garrus J; Brown S; Wollenberg L; Hogeland G; Wright D; Munson M; Rodriguez M; Gross S; Chantry D; Zou Y; Platanias L; Burgess LE; Pradhan K; Steidl U; Verma A
Cancer Res; 2016 Aug; 76(16):4841-4849. PubMed ID: 27287719
[TBL] [Abstract][Full Text] [Related]
16. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
17. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
18. The role of p38 mitogen-activated protein kinase in serum-induced leukemia inhibitory factor secretion by bone marrow stromal cells from pediatric myelodysplastic syndromes.
da Costa SV; Roela RA; Junqueira MS; Arantes C; Brentani MM
Leuk Res; 2010 Apr; 34(4):507-12. PubMed ID: 19913910
[TBL] [Abstract][Full Text] [Related]
19. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
20. p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration.
Studer RK; Aboka AM; Gilbertson LG; Georgescu H; Sowa G; Vo N; Kang JD
Spine (Phila Pa 1976); 2007 Dec; 32(25):2827-33. PubMed ID: 18246004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
